Advanced search
Publication Cover
Expert Opinion on Investigational Drugs Volume 14, 2005 - Issue 3
Submit an article Journal homepage
129
Views
63
CrossRef citations to date
0
Altmetric
Review

Assessment of pharmacology and potential anti-obesity properties of H3 receptor antagonists/inverse agonists

Arthur A Hancock Neuroscience Research, Abbott Laboratories, 100 Abbott Park Road, Abbott Park, Illinois 60064-6125, USA. [email protected]
&
Michael E Brune Metabolic Diseases Research, Abbott Laboratories, 100 Abbott Park Road, Abbott Park, Illinois 60064-6126, USA
Pages 223-241 | Published online: 22 Apr 2005

Bibliography

  • STEIN CJ, COLDITZ GA: The epidemic of obesity. J. Clin. Endocrinol (2004) 89:2522–2525.
  • MOKDADAH, MARKS JS, STROUP DF, GERBERDING JL: Actual causes of death in the United States, 2000. JAMA (2004) 291:1238–1245.
  • •A recent alarm that obesity will soon overtake cigarette smoking as the leading cause of preventable death in the US.
  • HEDLEY AA, OGDEN CL, JOHNSON CL, CARROLL MD, CURTIN LR, FLEGAL KM: Prevalence of overweight and obesity among US children, adolescents, and adults, 1999-2002. JAMA (2004) 291:2847–2850.
  • STURM R: Increases in clinically severe obesity in the United States, 1986-2000. Arch. Intern. Med. (2003) 163:2146–2148.
  • MAYOR S: New US Medicare policy changes ruling that obesity is not an illness. Br. Med. J. (2004) 329:252.
  • BRAY GA: Medical consequences of obesity../. Clin. Endocrinol (2004) 89:2583–2589.
  • MARCUS DA: Obesity and the impact of chronic pain. Clin. I Pain (2004) 20:186–191.
  • HESKETH K, WAKE M, WATERS E: Body mass index and parent-reported self-esteem in elementary school children: evidence for a causal relationship. Int. J. Obes. Reim. Metab. Disord. (2004) 28:1233–1237.
  • •Clinical study of 1100 children aged 5–10 years and relationships between body weight and self image.
  • COLDITZ GA: Economic costs of obesity and inactivity. Med. Sci. Sports Exerc. (1999) 31:S663–S667.
  • •Estimation of $70 x 109 as the direct costs of obesity in the US alone.
  • SCHEEN AJ: Current management strategies for coexisting diabetes mellitus and obesity. Drugs (2004) 63:1165–1184.
  • KLEIN S, BURKE LE, BRAY GA et al: Clinical implications of obesity with specific focus on cardiovascular disease: a statement for professionals from the American Heart Association Council on Nutrition, Physical Activity, and Metabolism: endorsed by the American College of Cardiology Foundation. Circulation (2004) 110:2952–2967.
  • •Clinical indications that even modest weight loss improved risk in cardiovascular disease.
  • PEPPARD PE, YOUNG T, PALTA M, DEMPSEY J, SKATRUD J: Longitudinal study of moderate weight change and sleep-disordered breathing. JAMA (2000) 284:3015–3021.
  • WEIGLE DS: Pharmacological therapy of obesity: Past, present and future. I Clin. Endocrinol. (2003) 88:2462–2469.
  • PEDERSON KJ, ROERIG JL, MITCHELL JE: Towards the pharmacotherapy of eating disorders. Expert Opin. Pharmacother. (2003) 4:11659–11678.
  • KORNER J, ARONNE LJ: Pharmacological approaches to weight reduction: Therapeutic targets. Endocrinol. (2004) 89:2616–2621.
  • DUHL DM, BOYCE RS: Obesity therapeutics: prospects and perspectives. Ann. Reports Med. Chem. (2003) 38:239–248.
  • LEIBOWITZ SF, WORTLEY KE: Hypothalamic control of energy balance: different peptides, different functions. Peptides (2004) 25:473–504.
  • •Recent thorough review of neuropeptides and energy balance.
  • BERTHOUD H-R: Multiple neural systems controlling food intake and body weight. Neurawi. Behav. Reviews. (2002) 26:393–428.
  • SCHWARTZ JC, ARRANG JM, GARBARG M, POLLARD H, RUAT M: Histaminergic transmission in the mammalian brain. Physiol Rev. (1991) 71:1–51.
  • ••Fundamental review of the neurotransmitter role of histamine.
  • TREESUKOSOL Y, ISHIZUKA T, YAMAMOTO T, YAMATODANI A: The effect of taste stimuli on histamine release in the anterior hypothalamus of rats. BE Res. (2003) 964:51–55.
  • BLANDINA P, BACCIOTTINI L, GIOVANNINI MG, MANNAIONI PF: H3 receptor modulation of the release of neurotransmitters in vivo. In: The Histamine H3 Receptor. R. Leurs, H. Timmerman (Eds), Elsevier, Amsterdam (1998):27–40.
  • ••Key monograph on multiple aspects of H3receptor pharmacology.
  • ONODERA K, YAMATODANI A, WATANABE T, WADA H: Neuropharmacology of the histaminergic neuron system in the brain and its relationship with behavioral disorders. Prog. Neurobiol (1994) 42:685–702.
  • MIKLOS IH, KOVACS KJ: Functional heterogeneity of the responses of histaminergic neuron subpopulations to various stress challenges. Eur. Neurawi. (2003) 18:3069–3079.
  • KUKKO-LUKJANOV T-K, PANULA P: Subcellular distribution of histamine, GABA and galanin in tuberomammilary neurons in vitro. Chem. Neuroanat. (2003) 25:279–292.
  • BROWN, RE, STEVENS DR, HAAS HL: The physiology of brain histamine. Prog. Neurobiol (2001) 63:637–672.
  • PASSANI MB, LIN JS, HANCOCK AA,CROCHET S, BLANDINA PA: The H3 receptor as a novel therapeutic target for cognitive and sleep disorders. Trends Pharmacol Sci. (2004) 25: 618–625.
  • BARNES W, BOYD D, HOUGH L: Dynamics of histamine H3 receptor antagonists on brain histamine metabolism: do all histamine H3 receptor antagonists act at a single site? Eur. Pharmacol (2001) 431:215–221.
  • HOUGH LB: Genomics meets histamine receptors: new subtypes, new receptors. Mol Pharmacol (2001) 59:415–419.
  • •Brief synopsis and comparison of four histamine receptor subtypes.
  • HARUSAWA S, ARAKI L, TERASHIMA H ET AL.: Efficient synthesis of trans- or cis-4 (5)-(5-aminomethyltetrahydrofuran-2-yOimidazoles via diazafulvene intermediates: synthetic approach toward human histamine Hcligands. Chem. Pharm. Bull. (2003) 51:832–837.
  • ESBENSHADE TA, KANG CH, KRUEGER KM et al.: Differential activation of dual signaling responses by human H1 and H2 histamine receptors. Receptor Signal Transduction Res. (2003) 23:17–31.
  • WANG L, GANTZ I, DELVALLE J: Histamine H2 receptor activates adenylate cyclase and PLC via separate GTP-dependent pathways. Am. I Physiol (1996) 271:G613–G620.
  • HANCOCK AA, ESBENSHADE TA, KRUEGER KM, YAO BB: Genetic and pharmacological aspects of histamine H3 receptor heterogeneity. Life Sci. (2003) 73:3043–3072.
  • •Review of interspecies differences in pharmacology and molecular biology of H3 receptors.
  • WIRSHING DA, WIRSHING WC, KYSAR L et al.: Novel antipsychotics: comparison of weight gain liabilities. Clin. Psych. (1999) 60:358–363.
  • McINTYRE RS, MANCINI DA, BASILE VS: Mechanisms of antipsychotic-induced weight gain. I Clin. Psych. (2001) 62\(Suppl. 23):23–29.
  • KROEZE WK, HUFEISEN SJ, POPADAK BA et al: HI-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. Neuropsychopharmacology (2003) 28:519–526.
  • BASILE VS, MASELLIS M, McINTYRE RS, MELTZER HY, LIEBERMAN JA, KENNEDY JL: Genetic dissection of atypical antipsychotic-induced weight gain: novel preliminary data on the pharmacogenetic puzzle. I Clin. Psych. (2001) 62\(Suppl. 23):45–66.
  • PILLOT C, HERON A, COCHOIS V et al.: A detailed mapping of the histamine H3 receptor and its gene transcripts in rat brain. Neurosci. (2002) 114: 173–193.
  • ANICHTCHIK OV, PEITSARO N, RINNE JO, KALIMO H, PANULA P: Distribution and modulation of histamine H-3 receptors in basal ganglia and frontal cortex of healthy controls and patients with Parkinson's disease. Neurobiol Disease (2001) 8:707–716.
  • YAMANAKA A, TSUJINO N, FUNAHASHI H et al.: Orexins activate histaminergic neurons via the orexin 2 receptor. Biochem. Biophys. Res. Comm. (2002) 290:1237–1245.
  • SCHLICKER E, KATHMANN M: Modulation of in vitro neurotransmission in the CNS and in the retina via H3 heteroreceptors. In: The Ilistamine 113 Receptor Leurs R, Timmerman H (Eds), Elsevier, Amsterdam (1998):13–26.
  • FOLOP AK, FOLDES A, BUZAS E et al: Hyperleptinemia, visceral adiposity and decreased glucose tolerance in mice with a targeted disruption of the histidine decarboxylase gene. Endocrinology (2003) 144:4306–4314.
  • FEKETE C, LIPOSITS Z: Histamine-immunoreactive neurons of the tuberomammillary nucleus are innervated by melanocyte stimulating hormone. Brant Res. (2003) 969:70–77.
  • NISHINO S, FUJIKI N, RIPLEY B et al:Decreased brain histamine content in hypocretin/orexin receptor-2 mutated narcoleptic dogs. Neurosci. Lett. (2001) 313:125–128.
  • KOK SW, OVEREEM S, VISSCHER TLS et al.: Hypocretin deficiency in narcoleptic humans is associated with abdominal obesity. Obes. Res. (2003) 11:1147–1154.
  • WEST RE JR, ZWEIG A, GANZOW RT, SIEGEL MI, EGAN RW: Biexponential kinetics of (R)-a- [3H] methylhistamine binding to the rat brain H3 histamine receptor. I Neurochem. (1990) 55:1612–1616.
  • LOVENBERG TW, PYATI J, CHANG H,WILSON SJ, ERLANDER MG: Cloning of rat histamine H3 receptor reveals distinct species pharmacological profiles. Pharmacol Exp. Ther. (2000) 293:771–778.
  • LIGNEAU X, MORISSET S, TARDIVELLACOMBE J et al: Distinct pharmacology of rat and human histamine H(3) receptors: role of two amino acids in the third transmembrane domain. BE Pharmacol (2000) 131:1247–1250.
  • YAO BB, HUTCHINS CW, CARR TL et al.: Direct ligand interactions with transmembrane domain 3 of the histamine H3 receptor protein. Neuropharmacology (2003) 44:773–786.
  • YAO BB, SHARMA R, CASSAR S, ESBENSHADE TA, HANCOCK AA: Cloning and pharmacological characterization of the monkey histamine H3 receptor. Eur. I Pharmacol (2003) 482:49–60.
  • DRUTEL G, PEITSARO N, KARLSTEDT J et al.: Identification of rat H3 receptor isoforms with different brain expression and signaling properties. Mol. Pharmacol (2001) 59:1–8.
  • WELLENDORPH P, GOODMAN MW, BURSTEIN ES, NASH NR, BRANN MR, WEINER DM: Molecular cloning and pharmacology of functionally distinct isoforms of the human histamine H3 receptor. Neuropharmacol (2002) 42:929–940.
  • MORISSET S, SASSE A, GBAHOU F et al.: The rat H3 receptor: gene organization and multiple isoforms. Biochem. Biophys. Res. Comm. (2001) 280:75–80.
  • CHEN J, LIU C, LOVENBERG TW: Molecular and pharmacological characterization of the mouse histamine H3 receptor. (2003) Eur. Pharmacol. 467: 57–65.
  • ROULEAU A, HERON A, COCHOIS V, PILLOT C, SCHWARTZ J-C, ARRANG J-M: Cloning and expression of the mouse histamine H3 receptor: evidence for multiple isoforms. Neurochem. 0004) 90:1331-1338.
  • MORISSET S, ROULEAU A, LIGNEAU X et al.: High constitutive activity of native H3 receptors regulates histamine neurons in brain. Nature (2000) 408:860–864.
  • •First description of the constitutive activity of H3 receptors.
  • ROULEAU A, LIGNEAU X, TARDIVELLACOMBE J et al.: Histamine H3-receptor-mediated [35S] GTPI4S1 binding: evidence for constitutive activity of the recombinant and native rat and human H3 receptors. BE J. Pharmacol (2002) 135:383–392.
  • WIELAND K, BONGERS G, YAMAMOTO Y et al: Constitutive activity of histamine H3 receptors stably expressed in SK-N-MC cells: Display of agonism and inverse agonism by H3 antagonists. Pharmacol Exp. Ther. (2001) 299:908–914.
  • YATES SL, PAWLOWSKI GP, ANTAL JM, ALI SM, BRUNDEN KR: Effects of a novel histamine H3 receptor antagonist, GT-2394 on food intake and weight gain in Sprague-Dawley rats. Abstract from the Society of Neuroscience, New Orleans, LA, USA (2000) 26:102.10.
  • YATES SL, POWLOWSKI GP, BABU JS, RAJAGOPALAN R, WAWRO WJ, TEDFORD C E: Inverse agonists of the histamine-3 receptor as appetite suppressants. Abstract of the American Chemical Society, New Orleans, LA, USA (2003) MEDI:2.
  • •Description of the pharmacology of GT-2394 and other similar antagonists, with an emphasis on a proposed link between inverse agonist activity and anti-obesity activity.
  • MASAKI T, YOSHIMATSU H, CHIBA S, WATANABE T, SAKATA T: Central infusion of histamine reduces fat accumulation and upregulates UCP family in leptin-resistant obese mice. Diabetes (2001) 50:376–384.
  • VAZIRI P, DANG K, ANDERSON GH: Evidence for histamine involvement in the effect of histidine loads on food and water intake in rats. I Num. (1997) 127:1519–1526.
  • YOSHIMATSU H, CHIBA S, TAJIMA D, AKEHI Y, SAKATA T: Histidine suppresses food intake through its conversion into neuronal histamine. Exp. Biol. Med. (2002) 227:63–68.
  • SAKATA T, YOSHIMATSU H, KUROKAWA M: Hypothalamic neuronal histamine: implications of its homeostatic control of energy metabolism. Nutrition (1997) 13:403–411.
  • SAKATA T, OOKUMA K, FUJIMOTO K, FUKAGAWA K, YOSHIMATSU H: Histaminergic control of energy balance in rats. Brain Res. Bull. (1991) 27:371–375.
  • MASAKI T, CHIBA S, YOSHIMICHI G et al.: Neuronal histamine regulates food intake, adiposity, and uncoupling protein expression in Agouti yellow (AY/a) obese mice. Endocrinology (2003) 144:2741–2748.
  • SAKATA T. YOSHIMATSU H, MASAKI T, TSUDA K: Anti-obesity actions of mastication driven by histamine neurons in rats. Exp. Biol. Med. (2003) 228:1106–1110.
  • MASAKI T, CHIBA S, YASUDA T et al:Involvement of hypothalamic histamine H1 receptor in the regulation of feeding rhythm and obesity. Diabetes (2004) 53:2250–2260.
  • ONODERA K, WATANABE T: Possible roles of brain histamine H3 receptors and the pharmacology of its ligands. Nihon Shinkei Seishin Yakurigaku Zasshi (1995) 15:87–102.
  • LEE DW, LEINUNG MC, ROZHAVSKAYA-ARENA M, GRASSO P: Leptin and the treatment of obesity: its current status. Eur. Pharmacol (2002) 440: 129–139.
  • LEVIN BE, DUNN-MEYNELL AA, BANKS WA: Obesity-prone rats have normal blood-brain barrier transport but defective central leptin signaling before obesity onset. Am. J. Physiol Regul Integr. Comp. Physiol (2004) 286:R143–R150.
  • HEGYI K, FULOP KA, KOVACS KJ, FALUS A, TOTH S: High leptin level is accompanied with decreased long leptin receptor transcript in histamine deficient transgenic mice. Immunol Lett. (2004) 92:193–197.
  • ITATEYAMA E, CHIBA S, SAKATA T, YOSHIMATSU H: Hypothalamic neuronal histamine in genetically obese animals: Its implication of leptin action in the brain. Exp. Biol. Med. (2003) 228:1132–1137.
  • MORIMOTO T, YAMAMOTO Y, MOBARAKEH JI et al: Involvement of the histaminergic system in leptin-induced suppression of food intake. Physiol Behav. (1999) 67:679–683.
  • TOFTEGAARD CL, KNIGGE U, KJAER AL, WARBERG J: The role of hypothalamic histamine in leptin-induced suppression of short-term food intake in fasted rats. Reg& Pept. (2003) 111:83–90.
  • MASAKI T, YOSHIMATSU H, CHIBA S, WATANABE T, SAKATA T: Targeted disruption of histamine HI-receptor attenuates regulatory effects of leptin on feeding, adiposity, and UCP family in mice. Diabetes (2001) 50:385–391.
  • YOSHIMATSU H, ITATEYAMA E, KONDOU S et al: Hypothalamic neuronal histamine as a target of leptin in feeding behavior. Diabetes (1999) 48:2286–2291.
  • MORIMOTO T, YAMAMOTO Y, YAMATODANI A: Leptin facilitates histamine release from the hypothalamus in rats. Brain Res. (2000) 868:367–369.
  • LECKLIN A, HERMONEN P, TARHANEN J, MANNISTO PT: An acute i.c.v. infusion of leptin has no effect on hypothalamic histamine and tele-methylhistamine contents in Wistar rats. Eur. Pharmacol (2000) 395:113–119.
  • MOLLET A, LUTZ TA, METERS, RIEDIGER T, RUSHING PA, SCHARRER E: Histamine H1 receptors mediate the anorectic action of the pancreatic hormone amylin. Am. Physiol Regul Integr. Comp. Physiol (2001) 281:R1442–R1448.
  • MOLLET A, METERS, RIEDIGER T, LUTZ TA: Histamine H1 receptors in the ventromedial hypothalamus mediate the anorectic action of the pancreatic hormone amylin. Peptides (2003) 24:155–158.
  • MORIMOTO T, YAMAMOTO Y, YAMATODANI A: Brain histamine and feeding behavior. Behav. Brain Res. (2001) 124:145–150.
  • YOSHIMATSU H, ITATEYAMA E, KONDOU S et al: Hypothalamic neuronal histamine as a target of leptin in feeding behavior. Diabetes (1999) 48:2286–2291.
  • COLLINS S, CAO WH, ROBIDOUX J:Learning new tricks from old dogs: 0-adrenergic receptors teach new lessons on firing up adipose tissue metabolism. Mol Endocrinology (2004) 18:2123–2131.
  • UNAMI A, SHINOHARA Y, KAJIMOTO K, BABA Y: Comparison of gene expression profiles between white and brown adipose tissues of rat by microarray analysis. Biochem. Pharmacol (2004) 67:555–564.
  • KARLSTEDT KA, AHMAN MJ, PANULA P: Histamine H3 receptor expression during rat development and in adult rat peripheral tissues. Abstracts of the Society of Neuroscience, San Diego, CA, USA (2001) 27:378.9.
  • KARLSTEDT K, AHMAN MJ, ANICHTCHIK OV, SOINILA S, PANULA P: Expression of the H3 receptor in the developing CNS and brown fat suggests novel roles for histamine. Mol Neurosci. (2003) 24:614–622.
  • TSUDA K, YOSHIMATSU H, NIIJIMA A, CHIBA S, OKEDA T, SAKATA T: Hypothalamic histamine neurons activate lipolysis in rat adipose tissue. Exp. Biol. Med. (2002) 227:208–213.
  • YASUDA T, MASAKI T, CHIBA S, KAKUMA T, SAKATA T, YOSHIMATSU H: L-Histidine stimulates sympathetic nerve activity to brown adipose tissue in rats. NeuroscL Lett. (2004) 362:71–74.
  • YASUDA T, MASAKI T, SAKATA T, YOSHIMATSU H: Hypothalamic neuronal histamine regulates sympathetic nerve activity and expression of uncoupling protein 1 mRNA in brown adipose tissue in rats. Neuroscience (2004) 125:535–540.
  • YOSHIMATSU H, TSUDA K, NIIJIMA A, TASUKAWA M, CHIBA S, SAKATA T: Histidine induces lipolysis through sympathetic nerve in white adipose tissue. Eur. Clin. Invest. (2002) 32:236–241.
  • LACOUR M, STERKERS I: Histamine and betahistine in the treatment of vertigo: elucidation of mechanisms of action. CNS Drugs (2001) 15:853–870.
  • SZELAG A, MALGORZATA T, MERWID-LAD A: Betahistine inhibits food intake in rats. Poi Pharmacol (2002) 53:701–707.
  • ROSSI R, DEL PRETE E, SCHARRER E:Effect of the HI-histamine receptor agonist betahistine on drinking and eating behavior in pygmy goats. Physiol Behav. (1999) 66:517–521.
  • ATTOUB S, MOIZO L, SOBHANI I, LAIGNEAU JP, LEWIN MJM, BADO A: The H3 receptor is involved in cholecystokinin inhibition of food intake in rats. Life Sci. (2001) 69:469–478.
  • ITOH E, FUJIMIYA M, INUI A: Thioperamide, a histamine H3 receptor antagonist, suppressed NPY-but not Dynorphin A-induced feeding in rats. Regul Pept. (1998) 75–76:373–376.
  • ITOH E, FUJIMIYA M, INUI A: Thioperamide, a histamine H3 receptor antagonist, powerfully suppresses peptide YY-induced food intake in rats. Biol. Psych. (1999) 45:475–481.
  • OOKUMA K, SAKATA T, FUKUGAWA K, YOSHIMATSU H, KUROKAWA M, FUJIMOTO K: Neuronal histamine in the hypothalamus suppressed food intake in rats. Brain Res. (1993) 628:235–242.
  • MERALI Z, BANKS K: Does the histaminergic system mediate bombesin/ GRP-induced suppression of food intake? Am. J. Physiol. (1994) 267:R1589–R1595.
  • NARUSET, ISHII R: Relationship between histamine receptors in the brain and diazepam-induced hyperphagia in rats. Pharmacol Biochem. Behav. (1995) 51:923–927.
  • UVEGES AJ, KOWAL D, ZHANG YX et al.: The role of transmembrane helix 5 in agonist binding to the human H3 receptor. Pharmacol Exp. Ther. (2002) 301:451–458.
  • LIEDTKE S, FLAU K, KATHMANN M et al.: Replacement of imidazole by a piperidine moiety differentially affects the potency of histamine H-3-receptor antagonists. Naunyn-Schmiedebergs Arch. Pharmacol (2003) 367: 43–50.
  • LIN JH, LU AYH: Inhibition and induction of cytochrome P450 and the clinical implications. Clin. Pharmacokinet. (1998) 35:361–390.
  • •Describes the potential linkage between imidazole-based compounds and drug-metabolising enzymes.
  • SLATER JW, ZECHNICH AD, HAXBY DG: Second-generation antihistamines. A comparative review. Drugs (1999) 57:31–47.
  • •Describes the potential linkage between imidazole-based compounds and drug-metabolising enzymes.
  • YANG R, HEY JA, ASLANIAN R, RIZZO CA: Coordination of histamine H3 receptor antagonists with human adrenal cytochrome P450 enzymes. Pharmacology (2002) 66:128–35.
  • •Describes the potential linkage between imidazole-based compounds and drug-metabolising enzymes.
  • SILVA C, MORI M, BORDI F et al.: Plasma concentration and brain penetration of the H3-receptor antagonist, thioperamide, in rats. II Farmaco (1997) 52:457–462.
  • CROW S, BROWN E: Investigational drugs for eating disorders. Expert Opin. Invest. Drugs (2003) 12:491–499.
  • MOCHIZUKI T, JANSEN FP, LEURS R et al.: Brain penetration of the histamine H3 receptor antagonists thioperamide and clobenpropit in rat and mouse, determined with ex vivo [125I]iodophenpropit binding. Brain Res. (1996) 743:178–183.
  • GANELLIN CR, LEURQUIN F, PIRIPITSI A et al: Synthesis of potent non-imidazole histamine H-3-receptor antagonists. Archly. Pharm. Pharm. Med. Chem. (1998) 331:395–404.
  • •First publication seeking non-imidazole H3 antagonists.
  • ESBENSHADE TA, KRUEGER KR, MILLER TR et al: Two novel and selective non-imidazole H3 receptor antagonists, A-304121 and A-317920: 1 In vitro pharmacological effects. I Pharmacol Exp. Ther. (2003) 305:887–896.
  • HANCOCK AA, BENNANI YL, BUSH EN et al.: Antiobesity effects of A-331440, a novel non-imidazole histamine H3 receptor antagonist. Eur. Pharmacol (2004) 487:183–197.
  • SINDELAR DK, SHEPPERD ML, PICKARD RT et al: Central H3R activation by thioperamide does not affect energy balance. Pharmcol Biochem. Behav. (2004) 78:275–283.
  • •Recent interesting data that links anti-obesity and the decreased food consumption effects of thioperamide to effects in a taste aversion test.
  • TOYOTA H, DUGOVIC C, KOEHL M et al.: Behavioral characterization of mice lacking histamine H-3 receptors. Mol. Pharmacol (2002) 62:389–397.
  • •First description of phenotypic behaviours of H3 receptor knockout mice.
  • TAKAHASHI K, SUWA H, ISHIKAWA T, KOTANI H: Targeted disruption of H3 receptors results in changes in brain histamine tone leading to an obese phenotype. ./. Clin. Invest. (2002) 110:1791–1799.
  • ••In-depth analysis of H3 knockout mice, particularly with respect to an obese phenotype.
  • VAN DEN POL AN: Weighing the role of hypothalamic feeding neurotransmitters. Neuron (2003) 40:1059–1061.
  • HANCOCK AA, BUSH EN, JACOBSEN PB, FAGHIH R, ESBENSHADE TA: H3 antagonists in models of obesity. Infiamm. Res. (2004) 53:S47–S48.
  • BRAY GA: A concise review on the therapeutics of obesity. Nutrition (2000) 16:953–960.
  • FOX GB, PAN JB, RADEK RJ et al: Two novel and selective non-imidazole H3 receptor antagonists, A-304121 and A-317920: 2, in vivo behavioral and neurophysiological characterization. Pharmacol Exper. Ther. (2003) 305:897–908.
  • ESBENSHADE TA, FOX GB, KRUEGER KM et al: Pharmacological and behavioral properties of A-349821, a selective and potent human histamine H3 receptor antagonist, Biochem. Pharmacol (2004) 68:933–945.
  • KOMATER VA, BROWMAN KE, CURZON P, HANCOCK AA, DECKER MW, FOX GB: H3 receptor blockade by thioperamide enhances cognition without inducing locomotor sensitization. Psychopharmacology (2003) 167:363–372.
  • •Examination of the potential for lack of abuse liability by the H3 antagonist thioperamide.
  • BJENNING C, JOHANNESSON U, JUUL A-G, LANGE KZ, RIMVALL K: Peripherally administered ciproxifan elevates hypothalamic histamine levels and potently reduces food intake in the Sprague-Dawley Rat. Abstract of the International Sendai Histamine Meeting, Sendai, Japan (2000) P-39:144.
  • BJENNING C, LIU W, RIMVALL K: Peripherally administered histamine H3 antagonist potently reduces snacking behavior in the obese Zucker rat. Abstract of the International Sendai Histamine Meeting, Sendai, Japan (2000) P-40:145.
  • ••A feeding model using a highly palatablefood, showing activity of ciproxifan to reduce feeding behaviour.
  • LIU H, KERDESKY FA, BLACK LA et al: An efficient multi-gram synthesis of the potent histamine H3 antagonist GT-2331 and the reassessment of the absolute configuration. I Org. Chem. (2004) 69:192–194.
  • KENAKIN T: Efficacy as a vector: the relative prevalence and paucity of inverse agonism. Mol Pharmacol(2004) 65:2–11.
  • COWART MD, FAGHIH R, CURTIS MP et al.: [2-(2 (A)-Methyl-pyrrolidine-1-yfiethyl]benzofuran-5-yfi-benzonitrile (ABT-239) and related 2-aminoethylbenzofurans H3 antagonists potently enhance cognition and attention. J. Med. Chem. (2005) 48:38–55.
  • FOX GB, ESBENSHADE TA, PAN JB et al.: Broad preclinical efficacy in cognition and schizophrenia by selective H3 receptor blockade. J. Pharmacol. Exp. Ther. (2004). (Submitted).
  • BARBIER AJ, BERRIDGE C, DUGOVIC C et al: Acute wake-promoting actions of JNJ-5207852, a novel, diamine-based H3 antagonist. BE J. Pharmacol (2004) 143:649–661.
  • PUDIAK CM, MILLER KM, ALUISIO LE et al: Effect of the novel histamine H3 antagonist JNJ-5207852 on drinking behavior in rats. Abstract from the Socieg, of Neurosdence, New Orleans, LA, USA (2003) 578.4.
  • STARK H: Recent advances in histamine H3/H4 ligands. Expert Opin. Ther. Patents (2003) 13:851–865.
  • COWART MD, ALTENBACH RA, BLACK LA, FAGHIH R, ZHAO C, HANCOCK AA: Medicinal chemistry and biological properties of non-imidazole histamine H3 antagonists. In: Mini-Reviews in Medicinal Chemistry R Leurs (Ed.), Bentham Science Publishers, Inc., The Netherlands (2004) 4:997–1010.
  • CURTIS MP, DWIGHT W, PRATT J et al.: D-Amino acid homopiperzine amides: Discovery of A-320436, a potent and selective non-imidazole histamine H3-receptor antagonist, Archly. Pharm. Pharm. Med. Chem. (2004) 337:219–229.
  • COWART M, PRATT JK, STEWART AO, BENNANI YL, ESBENSHADE TA, HANCOCK AA: A new class of potent non-imidazole H3 antagonists: 2-aminoethylbenzofurans. Bioorg. Med. Chem. Lett. (2004) 14:689–693.
  • RIMVALL K, MALMLOF K, CREMERS H et al: NNC-0038-0000-1049, a new potent histamine H3 receptor antagonist: in vitro characterization and effects in rat obesity models. Abstract of the European Histamine Research Socieg,, Noordwijkerhout, The Netherlands (2003):138.
  • ••Presentation of the anti-obesity propertiesof a novel, non-imidazole H3 receptor antagonist.
  • PESCHKE B, BAK S, HOHLWEG R et al: Cinnamic amides of (9-2-(aminomethyfipyrrolidines-discovery and SAR of the potent H3-antagonist NNC-0038-0000-1202. Abstract of the European Histamine Research Society Dusseldorf/Koln, Germany (2004) 94.
  • RIMVALL K, PESCHKE B, CREMERS TI et al: Body weight lowering effects of the cinnamic amide, NNC-0038-0000-1202, a novel histamine H3 receptor antagonist, in obese rodents. Abstract of the European Histamine Research Society Dusseldorf/Koln, Germany (2004) 98.
  • FAGHIH R, ESBENSHADE TA, KRUEGER KM et al: Structure-activity relationships of A-331440: a new histamine-3 antagonist with anti-obesity properties. Infiamm. Res. 53: S79–S80.
  • BUSH EN, SHAPIRO R, NUSS M et al: The histamine H3 receptor antagonist A-331440 decreases body weight in male C57BL/6J Mice with High Fat Diet-Induced Obesity. Abstr. Amer Diabetes Assoc., San Francisco, CA, USA (2002):1715–P
  • ••First presentation of the anti-obesity properties of A-331440 using a diet-induced mouse model of obesity.
  • BUSH E, DICKINSON RW, SHAPIRO R et al: Effects of histamine H3 receptor antagonist A-331440, triiodothyronine (T3) and 03-adrenergic agonist BRL-37344 (BRL) on body weight, food intake and metabolic rate in obese (ob/ob) mice. Abstr: Fed. Amer Socieg, Exp. Biol., San Diego, CA, USA. Fasebf (2003) 17:3763 571.4.
  • KRUEGER KM, Kang CH, Miller T et al: Pharmacological properties of the novel histamine H3 receptor antagonist, A-331440. Abstr. IUPHAR, San Francisco, CA, USA. Pharmacologist (2002) 44\(Suppl. 1):A196.
  • HANCOCK AA, KRUEGER KM, KANG CH et al.: Pharmacology of a novel histamine H3 receptor antagonist with favorable effects in diet-induced obesity in mice. Abstr. Soc. Neurasci. Orlando, FL, USA (2002) 28:869.10.
  • HANCOCK AA, BUSH EN, SHAPIRO R et al.: Antiobesity effects of novel, non-imidazole Histamine H3 Receptor antagonists exemplified by A-331440. emerging targets for the treatment of obesity. Abstract of the American Chemical Socieg,, New Orleans, LA USA (2003) MEDI:3.
  • HANCOCK, A, FOX G, BUSH E et al: Blockade of CNS-H3-Receptors by and Anti-obesity Effects of the Histamine H3 Receptor Antagonist, A-331440. Abstr. IUPHAR, San Francisco, CA, USA. Pharmacologist (2002) 44\(Suppl. 1):A157.
  • HANCOCK AA, BUSH EN, JACOBSEN PB, FAGHIH R, ESBENSHADE TA: H3 Antagonists in models of obesity. InlIamm. Res. (2004) 53:S47–S48.
  • MEDHURST AD, WILSON DM: Pre-clinical evaluation of novel H3 receptor antagonists. Abstr. Eur. Histamine Res. Soc. Dusseldorf/Koln, Germany (2004) 83.
  • HANCOCK AA, DIEHL MS, FEY T et al.: Antiobesity Evaluation of Histamine H3 Receptor (H3R) Antagonist Analogs of A-331440 with Improved Safety and Efficacy. Abstr. Eur. Histamine Res. Soc. Dusseldorf/Koln, Germany (2004) 54.
  • HANCOCK AA, DIEHL MS, FAGHIH R et al.: In vitro optimization of structure activity relationships of analogs of A-331440 combining radioligand receptor binding assays and micronucleus assays of potential antiobesity histamine H3 receptor antagonists. Basic Clin. Pharmacol Toxicol (2004) 95:144–152.
  • JONSSON S, HEDBLAD B, ENGSTROM G, NILSSON P, BERGLUND G, JANZON I: Influence of obesity on cardiovascular risk. Twenty-three-year follow-up of 22 025 men from an urban Swedish population. Int. I Obesity (2002) 26:1046–1053.
  • HANCOCK AA, BUSH EN, JACOBSEN PB, FAGHIH R, ESBENSHADE TA: H3 antagonists in models of obesity. Abstr Eur Histamine Res. Soc., Noordwijkerhout, The Netherlands. (2003) 82.
  • HANCOCK AA, FOX GB: Perspectives on cognitive domains, H3 receptor ligands and neurological disease. Expert Opin. Invest. Drugs (2004) 13:1237–1248.

Websites

  • http://www.hhs.gov/news/press/ 192004pres/ 20040715.htmllhttp://obesity Recent press release concerning the status of obesity as a disease.
  • http://obesityresearch.nih.gov/about/ strategic-plan.htm Information about NIH startegies for obesity research.
  • http://www.cdc.gov/nccdphp/dnpa/obesity/ trend/maps/index.htm Information and startling presentation on the growing obesity incidence in the US.
  • www.iotf.org/media/europeadults.pdf Information on obesity incidence increase in Western Europe.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.